

## **Zomedica to Report Second Quarter 2024 Financial Results and Provide Business Update on August 14 at 4:30 p.m. ET**

**ANN ARBOR, MI / August 1, 2024** / Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, will host a conference call and audio-only webcast on Wednesday, August 14, 2024, at 4:30 p.m. ET to discuss the Company’s operational and financial highlights for its second quarter ended June 30, 2024. A question-and-answer session will follow management’s prepared remarks.

**Event:** Zomedica Corp. Q2 2024 Financial Results Conference Call

**Date:** Wednesday, August 14, 2024

**Time:** 4:30 p.m. Eastern Time

**Live Call:** +1-800-717-1738 (U.S. Toll-Free) or +1-646-307-1865 (International)

**Webcast:** [LINK](#)

For interested individuals unable to join the conference call, a dial-in replay of the call will be available until Wednesday, August 28, 2024 at 11:59 PM ET and can be accessed by dialing +1-844-512-2921 (U.S. Toll-Free) or +1-412-317-6671 (International) and entering replay pin number: 1166273

### **About Zomedica**

Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet<sup>®</sup> shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi<sup>®</sup> Loop line of therapeutic devices and the TRUFORMA<sup>®</sup> diagnostic platform, the TRUVIEW<sup>™</sup> digital cytology system, and the VetGuardian<sup>®</sup> no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds \$2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. An NYSE American company, Zomedica grew revenue 33% in 2023 to \$25 million and maintains a strong balance sheet with approximately \$91 million in liquidity as of March 31, 2024. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit [www.zomedica.com](http://www.zomedica.com).

### **Follow Zomedica**

Email Alerts: <http://investors.zomedica.com>

LinkedIn: <https://www.linkedin.com/company/zomedica>

X (formerly Twitter): <https://x.com/zomedica>

Facebook: <https://m.facebook.com/zomedica>

Instagram: [https://www.instagram.com/zomedica\\_inc](https://www.instagram.com/zomedica_inc)

**SOURCE:** Zomedica Corp.

View the original press release on [accesswire.com](https://www.accesswire.com)